Breast diseases

PubMed Free Full Text

Breast cancer treatment: bisphosphonates, bone-modifying agents, bone health

Australia

• Royal Australian College of General Practitioners
  • Bone loss associated with aromatase inhibitor therapy for breast cancer and androgen deprivation therapy for prostate cancer

Canada

• Breast Cancer Research and Treatment
  • Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey [2021]

• Journal of Bone Oncology
  • Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting [2015]

Canada, United States

• American Society of Clinical Oncology
  • Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update [2022]
  • Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline [2017]

China

• Cancer Innovation
  • Clinical practice guidelines for full-cycle standardized management of bone health in breast cancer patients [2024]

Europe

• Annals of Oncology
  • Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel [2016]

• European Menopause and Andropause Society
  • Osteoporosis management in patients with breast cancer: EMAS position statement [2017]

Germany

• Breast Care
  • Breast Cancer and Osteoporosis – Management of Cancer Treatment-Induced Bone Loss in Postmenopausal Women with Breast Cancer [2014]

High-income countries

• Aging
  • Bisphosphonates and breast cancer survival: a meta-analysis and trial sequential analysis of 81508 participants from 23 prospective epidemiological studies [2021]

• Journal of Breast Cancer
  • Bisphosphonates and Prevention of the Perimenopausal Breast Cancer Recurrence: A Systematic Review and Meta-Analysis [2022]

India

• JCO Global Oncology
  • Cost-Effectiveness Analysis of Denosumab in the Prevention of Skeletal-Related Events Among Patients With Breast Cancer With Bone Metastasis in India [2024]

International

• Cochrane Database of Systematic Reviews
  • Bisphosphonates and other bone agents for breast cancer [2017]

• Journal of Bone Oncology
  • Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG [2017]

• PLoS ONE
  • The adverse effects of bisphosphonates in breast cancer: A systematic review and network meta-analysis [2021]

• Supportive Care in Cancer
  • MASCC/ISOO Clinical Practice Statement: Adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw [2024]

• Therapeutic Advances in Medical Oncology
  • The incidence and relative risk of adverse events in patients treated with bisphosphonate therapy for breast cancer: a systematic review and meta-analysis [2019]

Lithuania

• Medicina
  • Guidelines for diagnostics and treatment of aromatase inhibitor-induced bone loss in women with breast cancer: A consensus of Lithuanian medical oncologists, radiation oncologists, endocrinologists, and family medicine physicians [2014]

Republic of Korea

• Medicina
  • Osteoporosis Associated with Breast Cancer Treatments Based on Types of Hormonal Therapy: A Cross-Sectional Study Using Korean National Sample Data [2023]

• Scientific Reports
  • Risk factors for and incidence of osteoporosis in patients with breast cancer by gender : a nationwide cohort study [2025]

Singapore

• Annals Academy of Medicine Singapore
  • Singapore Cancer Network (SCAN) Guidelines for Bisphosphonate Use in the Adjuvant Breast Cancer Setting [2015]

United Kingdom

• National Institute for Health and Care Excellence
  • Adjuvant bisphosphonate therapy [2025]

United States

• American Society of Clinical Oncology
  • Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update [2017]

{Related topics}

• Topic
  • Osteoporosis: risk factors
  • Breast cancer treatment